Clinical Trial Update: Sacituzumab Govitecan in Metastatic Colorectal Cancer [Phase 2, Phase 3]

View source ↗

Summary

An ongoing Phase 2/Phase 3 trial of sacituzumab govitecan in metastatic colorectal cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: Metastatic Colorectal Cancer | Phase 2, Phase 3 | Status: RECRUITING